These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 2566377)
1. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Tsuda H; Hirohashi S; Shimosato Y; Hirota T; Tsugane S; Yamamoto H; Miyajima N; Toyoshima K; Yamamoto T; Yokota J Cancer Res; 1989 Jun; 49(11):3104-8. PubMed ID: 2566377 [TBL] [Abstract][Full Text] [Related]
2. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762 [TBL] [Abstract][Full Text] [Related]
3. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations. Gaffey MJ; Frierson HF; Williams ME Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628 [TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for recurrent breast cancer: univariate and multivariate analyses including histologic grade and amplification of the c-erbB-2 proto-oncogene. Tsuda H; Tsugane S; Fukutomi T; Nanasawa T; Yamamoto H; Hirohashi S Jpn J Clin Oncol; 1992 Aug; 22(4):244-9. PubMed ID: 1359174 [TBL] [Abstract][Full Text] [Related]
5. Significance of int-2/hst-1 coamplification as a prognostic factor in patients with esophageal squamous carcinoma. Kitagawa Y; Ueda M; Ando N; Shinozawa Y; Shimizu N; Abe O Cancer Res; 1991 Mar; 51(5):1504-8. PubMed ID: 1997190 [TBL] [Abstract][Full Text] [Related]
6. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer. Champème MH; Bièche I; Hacène K; Lidereau R Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157 [TBL] [Abstract][Full Text] [Related]
7. Analysis of the int-1, int-2, c-myc, and neu oncogenes in human breast carcinomas. Meyers SL; O'Brien MT; Smith T; Dudley JP Cancer Res; 1990 Sep; 50(18):5911-8. PubMed ID: 1975511 [TBL] [Abstract][Full Text] [Related]
8. Proto-oncogene amplification and human breast tumor phenotype. Adnane J; Gaudray P; Simon MP; Simony-Lafontaine J; Jeanteur P; Theillet C Oncogene; 1989 Nov; 4(11):1389-95. PubMed ID: 2554239 [TBL] [Abstract][Full Text] [Related]
9. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Guérin M; Barrois M; Terrier MJ; Spielmann M; Riou G Oncogene Res; 1988; 3(1):21-31. PubMed ID: 2905033 [TBL] [Abstract][Full Text] [Related]
10. [New prognostic factors in patients with esophageal squamous carcinoma]. Ueda M Gan To Kagaku Ryoho; 1992 Jan; 19(1):20-5. PubMed ID: 1530906 [TBL] [Abstract][Full Text] [Related]
11. Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer. Le Roy X; Escot C; Brouillet JP; Theillet C; Maudelonde T; Simony-Lafontaine J; Pujol H; Rochefort H Oncogene; 1991 Mar; 6(3):431-7. PubMed ID: 1707153 [TBL] [Abstract][Full Text] [Related]
12. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285 [TBL] [Abstract][Full Text] [Related]
13. Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoietic growth factor release by tumor cells? Tang RP; Kacinski B; Validire P; Beuvon F; Sastre X; Benoit P; dela Rochefordière A; Mosseri V; Pouillart P; Scholl S J Cell Biochem; 1990 Nov; 44(3):189-98. PubMed ID: 1980125 [TBL] [Abstract][Full Text] [Related]
14. An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas. Walker RA; Senior PV; Jones JL; Critchley DR; Varley JM J Pathol; 1989 Jun; 158(2):97-105. PubMed ID: 2569035 [TBL] [Abstract][Full Text] [Related]
15. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. Garcia I; Dietrich PY; Aapro M; Vauthier G; Vadas L; Engel E Cancer Res; 1989 Dec; 49(23):6675-9. PubMed ID: 2573420 [TBL] [Abstract][Full Text] [Related]
16. c-erbB-2 amplification in node-negative human breast cancer. Ro JS; el-Naggar A; Ro JY; Blick M; Frye D; Fraschini G; Fritsche H; Hortobagyi G Cancer Res; 1989 Dec; 49(24 Pt 1):6941-4. PubMed ID: 2573424 [TBL] [Abstract][Full Text] [Related]
17. [Correlation between DNA content and amplification of oncogenes (c-myc, L-myc, c-erbB-2) and correlation with prognosis in 143 cases of resected lung cancer]. Chiba W; Sawai S; Hanawa T; Ishida H; Matsui T; Kosaba S; Watanabe S; Hatakenaka R; Matsubara Y; Funatsu T Gan To Kagaku Ryoho; 1993 Apr; 20(6):824-7. PubMed ID: 8098200 [TBL] [Abstract][Full Text] [Related]
18. BCL-1 participates in the 11q13 amplification found in breast cancer. Theillet C; Adnane J; Szepetowski P; Simon MP; Jeanteur P; Birnbaum D; Gaudray P Oncogene; 1990 Jan; 5(1):147-9. PubMed ID: 2181375 [TBL] [Abstract][Full Text] [Related]
19. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Varley JM; Swallow JE; Brammar WJ; Whittaker JL; Walker RA Oncogene; 1987; 1(4):423-30. PubMed ID: 3330785 [TBL] [Abstract][Full Text] [Related]
20. Quantitative detection of amplification of proto-oncogenes in breast cancer. Chen Y; Dong J; Lu Y; McGee JO Chin Med J (Engl); 1995 Nov; 108(11):849-54. PubMed ID: 8585979 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]